Skip to content

Standard Testing Pathway for High-Throughput Sequencing in Precision Oncology

Standard Testing Pathway for High-Throughput Sequencing in Precision Oncology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127957
Enrollment
Unknown
Registered
2026-07-10
Start date
2026-07-15
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Cohort of lung cancer patients:None
Colorectal cancer patient cohort:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Retrospective study: Patients who were previously diagnosed with lung cancer or colorectal cancer and have undergone high-throughput sequencing testing; 2.Retrospective study: The collected indicators include patients' clinical information (such as age, gender, pathological type, stage, treatment plan, and prognosis), high-throughput sequencing-related data (such as sampling time, specimen type, detection methods, gene mutation types and frequencies, gene copy number variations, fusion genes, etc.), other tumor treatments, monitoring-related tests and their results (PCR, immunohistochemistry, imaging tests, etc.), testing medical costs, treatment costs, and so on. 3. Prospective study: (1) Recruit from February 2025 to February 2029. During the clinical diagnosis and treatment process, or through screening based on the Hospital's LIS System (Laboratory InformationSystem) and HIS system (Hospital InformationSystem) to meet the requirements, And patients who voluntarily participated in this study. (2) Include patients with clinically confirmed lung cancer or colorectal cancer.

Exclusion criteria

Exclusion criteria: 1.Retrospective study: None 2. Prospective study: (1) Age <18 years old; (2) Incomplete clinical information; (3) Lactation and pregnancy; (4) Suffering from severe mental disorders such as epilepsy, etc. (5) Patients who refuse to sign informed consent; (6) Patients who, as determined by the researcher, are not suitable for inclusion in the trial.

Design outcomes

Primary

MeasureTime frame
Gene locus detection rate;Medical costs;Turnaround Time;

Secondary

MeasureTime frame
Objective Response Rate (ORR);Progression Free Survival;

Countries

China

Contacts

Public ContactYing Binwu

West China Hospital of Sichuan University

binwuying@126.com+86 28 85422533

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026